Testing JP-1366 to prevent NSAID-related stomach ulcers
Part of Digestive system clinical trials.
This trial tests a new drug called JP-1366 to see if it can prevent stomach ulcers caused by long-term NSAID use (like ibuprofen or naproxen) for conditions such as arthritis. It may be a good fit if you need to take NSAIDs for at least 24 weeks and have a higher risk of ulcers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have a condition like rheumatoid arthritis, osteoarthritis, or another disease that requires long-term NSAID treatment (at least 24 weeks).
- You have at least one risk factor for developing a stomach ulcer (for example, being over 65, taking blood thinners or steroids, or past ulcer history).
- You can undergo an upper endoscopy (a tube with a camera placed down your throat to look at your stomach).
- You do not currently have an active or healing stomach or duodenal ulcer.
- You have not had cancer (except some skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Ilaprazole 10 mg to see if it can prevent stomach ulcers caused by NSAIDs (pain relievers like ibuprofen). If you take NSAIDs regularly and have a higher risk of ulcers, this trial may help protect your stomach.
This trial tests a new medicine, fexuprazan, to see if it can prevent stomach ulcers caused by taking NSAID pain relievers for a long time. If you need daily NSAIDs for arthritis or other muscle/bone pain, this medicine might help protect your stomach.
This trial tests how a new drug, JP-1366, interacts with several common heart and blood medications (clopidogrel, aspirin, atorvastatin, and apixaban) in healthy volunteers. It aims to see if the combination is safe and how the drugs affect each other in the body.
This study tests an investigational medication called JP-1366 for people with non-erosive GERD, a condition where acid reflux causes heartburn and regurgitation but no visible damage to the esophagus. The goal is to see if this new treatment can safely reduce symptoms better than a placebo.
This trial tests a new medication (JP-1366) to see if it helps prevent acid reflux damage from coming back. You may join if you have had erosive esophagitis that healed after treatment, and you are currently doing well without other serious conditions.
This trial tests a new medication, JP-1366, for people with reflux esophagitis (damage to the esophagus from stomach acid). It aims to see if the drug is safe and effective at healing the esophagus and relieving symptoms like heartburn and regurgitation.
Hear when a new Peptic Ulcer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.